Replies to post #71962 on Biotech Values

[DewDiligence]

RPRX – In other words, you’ve never seen dropouts in a clinical trial reported as a ratio of one set of arms to another. (You could’ve just said this and saved on the back and forth.)

AE rates, cure rates, ... are easily more important than dropout rates and are given in ratios all the time.

Do you seriously want to continue this feeble line of debate?

Let’s cut through the BS: Any reasonable person would expect the dropout rate on placebo to be high-sky in a trial whose objective was mitigation of pain, as was the case for the trial in question. Hence the ratio of the placebo dropout rate to the Proellex dropout rate is an inherently bogus metric. What’s much more relevant, IMO, is how many of the patients on Proellex dropped out and why they dropped out. Why did RPRX feel compelled to hide these data from public view?